Benzinga··Vandana SinghNovo Nordisk Advances Oral GLP-1 Therapy for Young Diabetics
Novo Nordisk reports positive phase 3a trial results for oral semaglutide in children with type 2 diabetes, planning 2026 regulatory filings for potential first pediatric GLP-1 approval.
NVOregulatory approvalOzempic